Emphysema News and Research

Latest Emphysema News and Research

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

9 Mar 2011

Journal of Chronic Obstructive Pulmonary Disease becomes official journal of COPD Foundation

COPD: Journal of Chronic Obstructive Pulmonary Disease, the first journal dedicated to publishing a range of research on the impact of COPD, has become the official journal of the COPD Foundation.

5 Mar 2011

ATS releases new report detailing emerging trends in HIV-linked pulmonary disease management

The American Thoracic Society has released a new report detailing recent global changes in the management of human immunodeficiency virus-associated pulmonary disease.

4 Mar 2011

Level 3, ALA sign agreement to provide DIA, voice services to improve lung health awareness

Level 3 Communications, Inc. today announced that it has signed an agreement with the American Lung Association of the Midland States, a non-profit healthcare organization serving Kentucky, Michigan, Ohio and Tennessee, to provide dedicated Internet access and voice services in support of its mission to improve lung health awareness.

2 Mar 2011

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) has completed the first two transcatheter aortic valve implants (TAVI) ever achieved in Michigan. The procedures are a part of CVI's participation in the Medtronic CoreValve® U.S. Clinical Trial. This multi-state trial will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis.

2 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

AHRQ: Low-income rural Americans with COPD more likely to be hospitalized

Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

18 Feb 2011

Certain uses of terbutaline could lead to maternal heart problems and death, FDA warns

The U.S. Food and Drug Administration is warning that terbutaline administered by injection or through an infusion pump should not be used in pregnant women for prevention or prolonged (beyond 48-72 hours) treatment of preterm labor due to the potential for serious maternal heart problems and death. In addition, oral terbutaline tablets should not be used for prevention or treatment of preterm labor.

18 Feb 2011

Extensive, reversible changes in heart take place when exposed to low oxygen levels

From the highest mountaintop comes a new research report in the FASEB Journal that gets to the bottom of what happens to the hearts of people when exposed to low-levels of oxygen, such as those on Mount Everest or in the intensive care unit of a hospital.

1 Feb 2011

Study identifies gaps in primary health care for seniors with multiple chronic conditions

The number of health care services seniors use is determined more by the number of chronic conditions they have than by their age, according to a new study from the Canadian Institute for Health Information.

28 Jan 2011

CSL Behring receives marketing approval for HAE drug Berinert in Israel

CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.

28 Jan 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have made a breakthrough in understanding the mechanisms behind the most severe form of hereditary emphysema and how protein treatments can improve the condition. The findings of this study may also lead to new treatments for patients with smoker's emphysema.

24 Jan 2011

USPTO grants KL4 surfactant combination product patent to Discovery Labs

Discovery Laboratories, Inc. has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 7,863,241 titled "Compositions for Treatment and Prevention of Pulmonary Conditions." The patent provides broad coverage for compositions that employ a combination of certain pulmonary surfactants with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

19 Jan 2011

Emphysema News and Research

Latest Emphysema News and Research

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Journal of Chronic Obstructive Pulmonary Disease becomes official journal of COPD Foundation

ATS releases new report detailing emerging trends in HIV-linked pulmonary disease management

Level 3, ALA sign agreement to provide DIA, voice services to improve lung health awareness

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

FDA approves roflumilast to treat COPD

New drug approved for COPD by the FDA

AHRQ: Low-income rural Americans with COPD more likely to be hospitalized

Certain uses of terbutaline could lead to maternal heart problems and death, FDA warns

Extensive, reversible changes in heart take place when exposed to low oxygen levels

Study identifies gaps in primary health care for seniors with multiple chronic conditions

CSL Behring receives marketing approval for HAE drug Berinert in Israel

Baxter fourth quarter net income declines 26% to $423 million

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

USPTO grants KL4 surfactant combination product patent to Discovery Labs

New study provides insight into developing therapeutics for airway disease

Investigators receive two Alpha-1 Foundation grants for research on lung disorder

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Emphysema News and Research

Latest Emphysema News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in